Immunic
IMUX
81 hedge funds and large institutions have $200M invested in Immunic in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 29 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
53% more capital invested
Capital invested by funds: $131M → $200M (+$69M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $8.88M
21% more funds holding
Funds holding: 67 → 81 (+14)
1.12% more ownership
Funds ownership: 5.22% → 6.34% (+1.1%)
31% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$11.6M |
| 2 |
RI
RTW Investments
New York
|
+$11.5M |
| 3 |
CC
Commodore Capital
New York
|
+$10.3M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$7.91M |
| 5 |
Janus Henderson Group
London,
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$1.67M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.58M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$965K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$695K |
| 5 |
Two Sigma Investments
New York
|
-$628K |
IMUX Hedge Fund Activity: Q1 2022 in Review
81 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2022, worth a combined $200M — up 53% from $131M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IMUX positions and 4 closed out — a net gain of 14 holders — while 20 added to existing stakes and 29 trimmed.
The largest buyer was Cowen and Company, adding an estimated $11.6M. The largest seller was State Street, cutting an estimated $1.67M.
- 81 institutional investors held Immunic (IMUX) as of Q1 2022, up from 67 in Q4 2021.
- Funds reported $200M of Immunic stock for Q1 2022, up 53% quarter-over-quarter.
- 18 funds opened new Immunic positions in Q1 2022 and 4 closed out, a net change of +14 holders.
- The largest Immunic buyer in Q1 2022 was Cowen and Company, an estimated $11.6M added.
- The largest Immunic seller in Q1 2022 was State Street, an estimated $1.67M sold.
Based on aggregated 13F filings for Q1 2022.